PhaseBio Pharma 
Welcome,         Profile    Billing    Logout  
 5 Products   1 Disease  5 Products   2 Trials   224 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PB6440 / CORXEL
NCT06183671: JX09 SAD/MAD in Healthy Participants

Recruiting
1
92
RoW
JX09 or placebo SAD, JX09 or placebo MAD, JX09
Ji Xing Pharmaceuticals Australia Pty Ltd, Novotech (Australia) Pty Limited
Resistant Hypertension
12/24
12/24
bentracimab (PB2452) / SFJ Pharma, PhaseBio Pharma
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
NCT05162131: Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

Terminated
1
34
RoW
Bentracimab (PB2452) 100 mg or Placebo, Bentracimab (PB2452) 300 mg or Placebo, Bentracimab (PB2452) 1000 mg or Placebo, Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment), Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment), Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment), Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)
SFJ Pharmaceuticals, Inc., SFJ Pharmaceuticals, Inc.
Healthy
12/22
12/22
froniglutide (PF1801) / ImmunoForge
FROG, NCT05833711: Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy

Recruiting
2
39
RoW
Froniglutide, PF1801, Placebo
Immunoforge Co. Ltd.
Dermatomyositis, Polymyositis, Idiopathic Inflammatory Myopathies
03/25
09/25
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
PB6440 / CORXEL
NCT06183671: JX09 SAD/MAD in Healthy Participants

Recruiting
1
92
RoW
JX09 or placebo SAD, JX09 or placebo MAD, JX09
Ji Xing Pharmaceuticals Australia Pty Ltd, Novotech (Australia) Pty Limited
Resistant Hypertension
12/24
12/24
bentracimab (PB2452) / SFJ Pharma, PhaseBio Pharma
REVERSE-IT, NCT04286438 / 2019-004457-92: Bentracimab in Ticagrelor-treated Patients With Uncontrolled Bleeding or Requiring Urgent Surgery or Invasive Procedure

Completed
3
226
Europe, Canada, US, RoW
Bentracimab (PB2452) Infusion
SFJ Pharmaceuticals, Inc.
Hemorrhage, Urgent Surgery, Invasive Procedure
09/24
09/24
NCT05162131: Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 With and Without Ticagrelor Pretreatment in Chinese Healthy Volunteers

Terminated
1
34
RoW
Bentracimab (PB2452) 100 mg or Placebo, Bentracimab (PB2452) 300 mg or Placebo, Bentracimab (PB2452) 1000 mg or Placebo, Bentracimab (PB2452) 1000 mg or Placebo (With Ticagrelor Pre-Treatment), Bentracimab (PB2452) 3000 mg or Placebo (With Ticagrelor Pre-Treatment), Bentracimab (PB2452) 9000 mg or Placebo (With Ticagrelor Pre-Treatment), Bentracimab (PB2452) 18000 mg or Placebo (With Ticagrelor Pre-Treatment)
SFJ Pharmaceuticals, Inc., SFJ Pharmaceuticals, Inc.
Healthy
12/22
12/22
froniglutide (PF1801) / ImmunoForge
FROG, NCT05833711: Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy

Recruiting
2
39
RoW
Froniglutide, PF1801, Placebo
Immunoforge Co. Ltd.
Dermatomyositis, Polymyositis, Idiopathic Inflammatory Myopathies
03/25
09/25

Download Options